Deep learning identifies Acute Promyelocytic Leukemia in bone marrow smears

Media type: E-Article

Title: Deep learning identifies Acute Promyelocytic Leukemia in bone marrow smears

Contributor: Eckardt, Jan‑Niklas [Author]; Schmittmann, Tim [Author]; Riechert, Sebastian [Author]; Kramer, Michael [Author]; Shekh Sulaiman, Anas [Author]; Sockel, Katja [Author]; Kroschinsky, Frank [Author]; Schetelig, Johannes [Author]; Wagenführ, Lisa [Author]; Schuler, Ulrich [Author]; Platzbecker, Uwe [Author]; Thiede, Christian [Author]; Stölzel, Friedrich [Author]; Röllig, Christoph [Author]; Bornhäuser, Martin [Author]; Wendt, Karsten [Author]; Middeke, Jan Moritz [Author]

Published: Berlin; Heidelberg: Springer, [2024]

Language: English

DOI: 10.1186/s12885-022-09307-8

Keywords: Akute myeloische Leukämie ; Deep learning ; Artificial intelligence ; Bone marrow smear ; Akute promyelozytäre Leukämie ; Knochenmarksabstrich ; Künstliche Intelligenz ; Maschinelles Lernen ; Acute promyelocytic leukemia ; Acute myeloid leukemia

Origination:

Footnote:

Description: Background: Acute promyelocytic leukemia (APL) is considered a hematologic emergency due to high risk of bleeding and fatal hemorrhages being a major cause of death. Despite lower death rates reported from clinical trials, patient registry data suggest an early death rate of 20%, especially for elderly and frail patients. Therefore, reliable diagnosis is required as treatment with differentiation-inducing agents leads to cure in the majority of patients. However, diagnosis commonly relies on cytomorphology and genetic confirmation of the pathognomonic t(15;17). Yet, the latter is more time consuming and in some regions unavailable. - Methods: In recent years, deep learning (DL) has been evaluated for medical image recognition showing outstanding capabilities in analyzing large amounts of image data and provides reliable classification results. We developed a multi-stage DL platform that automatically reads images of bone marrow smears, accurately segments cells, and subsequently predicts APL using image data only. We retrospectively identified 51 APL patients from previous multicenter trials and compared them to 1048 non-APL acute myeloid leukemia (AML) patients and 236 healthy bone marrow donor samples, respectively. - Results: Our DL platform segments bone marrow cells with a mean average precision and a mean average recall of both 0.97. Further, it achieves high accuracy in detecting APL by distinguishing between APL and non-APL AML as well as APL and healthy donors with an area under the receiver operating characteristic of 0.8575 and 0.9585, respectively, using visual image data only. - Conclusions: Our study underlines not only the feasibility of DL to detect distinct morphologies that accompany a cytogenetic aberration like t(15;17) in APL, but also shows the capability of DL to abstract information from a small medical data set, i. e. 51 APL patients, and infer correct predictions. This demonstrates the suitability of DL to assist in the diagnosis of rare cancer entities. As our DL platform predicts APL from bone marrow smear images alone, this may be used to diagnose APL in regions were molecular or cytogenetic subtyping is not routinely available and raise attention to suspected cases of APL for expert evaluation.

Access State: Open Access

Rights information: Attribution (CC BY)

Search in field:

Recently searched for: